NCT02535806View on ClinicalTrials.gov

Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

May 25, 2017

Study Completion Date

May 25, 2017

Conditions
Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma
Interventions
DRUG

Velcade

4 doses of study drug will be given.

DRUG

Methotrexate

Intrathecal dose For CNS negative patients, Day 1 and Day 8

DRUG

Methotrexate / Hydrocortisone / Cytarabine

Intrathecal dose for CNS positive patients, Day 1, 8, 15, 22

DRUG

Dexamethasone

Days 1-5 and 15-19

DRUG

Mitoxantrone

Days 1 and 2

DRUG

Vincristine

Days 1, 8, 15, 22

DRUG

Pegaspargase

Days 3 and 17

Trial Locations (1)

64108

Children's Mercy Hospital, Kansas City

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Children's Mercy Hospital Kansas City

OTHER